{"type":"trials","record":{"id":41900,"source_id":"clinicaltrials-gov","external_id":"NCT03861234","title":"A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)","brief_summary":"This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated. People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Boehringer Ingelheim","enrollment":43,"countries":["United States","Germany","United Kingdom"],"start_date":"2019-06-27","completion_date":"2023-11-01","last_update_date":"2024-11-20","source_url":"https://clinicaltrials.gov/study/NCT03861234","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"55 Years","comparator":null,"organization":"Boehringer Ingelheim","interventions":["BI 836880"],"registry_source":"ClinicalTrials.gov","outcome_measures":["SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — From drug administration until the end of tr…","MRD-part: Number of Participants With Drug Related Adverse Events (AEs) — From first drug administration until the end…","SRD-part: Number of Participants With Drug Related Adverse Events (AEs) — From drug administration until the end of tri…","SRD-part: Number of Participants With Any Ocular Adverse Events in the Study Eye — From drug administration until the e…","MRD-part: Percentage Change From Baseline in Central Subfield Thickness (CSFT) in the Study Eye at Week 12 — At baselin…","MRD-part: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 12 — At baseline and at…","MRD-part: Time to Recurrence in the Study Eye From Last Administration at Each Visit — From last drug administration at…","MRD-part: Number of Participants With Any Ocular Adverse Events in the Study Eye — From first drug administration until…"],"design_description":"NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Wet Macular Degeneration","BI 836880"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03861234","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-06-27 to 2023-11-01","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.889Z","intervention":["BI 836880"],"participants":43,"study_design":"NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs) — From drug administration until the end of tr…","MRD-part: Number of Participants With Drug Related Adverse Events (AEs) — From first drug administration until the end…","SRD-part: Number of Participants With Drug Related Adverse Events (AEs) — From drug administration until the end of tri…","SRD-part: Number of Participants With Any Ocular Adverse Events in the Study Eye — From drug administration until the e…","MRD-part: Percentage Change From Baseline in Central Subfield Thickness (CSFT) in the Study Eye at Week 12 — At baselin…","MRD-part: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 12 — At baseline and at…","MRD-part: Time to Recurrence in the Study Eye From Last Administration at Each Visit — From last drug administration at…","MRD-part: Number of Participants With Any Ocular Adverse Events in the Study Eye — From first drug administration until…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41900","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}